Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned: building her career, saving for a home, and mapping out her future. But a stage 3 triple-negative breast cancer diagnosis abruptly halted those plans. The most aggressive subtype, triple-negative breast cancer, forced Vanessa to pivot from caregiver to patient, navigating a world she thought she knew but soon realized she didn't. "I've taken care of patients my whole life," she says, "but I didn't really know what breast cancer truly entailed."
Her initial treatment began swiftly, but the cancer spread, leading to a metastatic triple-negative breast cancer diagnosis. For Vanessa, this was devastating: "It was just an awful feeling to know you have to go through treatment again." Triple-negative breast cancer tends to grow and spread quickly, and for about half of women with the metastatic form, the first treatment may be the only chance to prevent further growth, making the initial treatment choice critical. This subtype also disproportionately affects younger women and Black and Hispanic women, highlighting the need for accessible education and advanced treatment options.
Historically, metastatic triple-negative breast cancer treatment was limited to chemotherapy, which impacts cancer cells but also normal cells. However, Vanessa's doctor suggested a clinical trial for a newer class of medicine called antibody-drug conjugates (ADCs). These drugs are designed to target specific markers on cancer cells and deliver medication directly to them, unlike traditional chemotherapy. Until recently, ADCs were used later in treatment, but now they may be offered as a first-line therapy. Innovations like ADCs have already helped many patients by keeping cancer from growing, allowing individuals like Vanessa to plan for the future, whether that's a girls' trip or time with family. However, not all ADCs are the same; safety and efficacy vary, and not every patient is eligible.
Vanessa's medical oncologist, Dr. Gregory Vidal, MD, PhD, Director of Clinical Research at West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, emphasizes the importance of individualized care: "When selecting treatment, it's important to consider patients' goals, wishes and needs so that we can try to realistically plan around those. All patients are different and may qualify for different ADCs." He encourages patients to have open conversations with their care team and ask questions about treatment goals at their stage of care. For many living with metastatic breast cancer, treatment continues for life, aiming to manage the disease and slow progression while maintaining quality of life.
Vanessa leaned on her support network, focusing on "faith over fear" by planning outings around her treatments and staying positive. She advises others to advocate for themselves: "You definitely have a fight in front of you, but you can get through this. You have to do your research and get answers." Her story underscores the importance of understanding treatment options, like ADCs, and having informed discussions with healthcare providers. To learn more about how patients like Vanessa navigate ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.
